Search results for "bisphosphonate"

showing 10 items of 184 documents

Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Ca…

2018

The study presents a report of 58 metastatic cancer patients who developed osteonecrosis of the jaws after being treated with zoledronic acid and taxanes, plus corticosteroids. A retrospective analysis of data registered in the archives of two Italian osteonecrosis of the jaws treatment centers, who are based at the University of Messina and at the University of Palermo, was performed in order to study, in these patients, demographic data and characteristics such as frequency of cancer location, lines of therapy, frequency of cancer drugs, presence/absence of oral trigger, number, location, and stage of jaw osteonecrosis. It was found that the majority of patients developed advanced stages …

DrugGenetics and Molecular Biology (all)Malemedicine.medical_specialtyExacerbationArticle SubjectImmunology and Microbiology (all)media_common.quotation_subjectlcsh:MedicineClinical manifestationBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsmedicineHumansDrug InteractionsStage (cooking)media_commonRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)General Immunology and MicrobiologyBone Density Conservation AgentsDiphosphonatesbusiness.industrylcsh:ROsteonecrosisSoft tissueCancer030206 dentistryGeneral Medicinemedicine.diseaseZoledronic acidBiochemistry Genetics and Molecular Biology (all) Immunology and Microbiology (all)Italy030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleTaxoidsbusinessOsteonecrosis of the jawBiochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)medicine.drugResearch ArticleBioMed Research International
researchProduct

Adverse drug reactions in the oral cavity

2012

Several drugs may have a number of adverse reactions (ADRs) involving the oro-facial region. The dose of the drug and the time required for the reaction to take place are relevant parameters; nonetheless, ADRs mechanisms are not always known and ADRs are not always predictable since aspects other than drug pharmacodynamics and/or pharmacokinetics, as well as various interacting variables contribute to the final outcome. All tissues and many functions of the oral cavity can be affected. In particular, salivary function is fre- quently involved and hypo-salivation is the main manifestation; several mucosal lesions with different morphology (ulcerations, vesiculo- bullous lesions, white lesion…

Drugdrug pharmacodynamicosteonecrosimedicine.medical_specialtyTime FactorsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectSettore MED/50 - Scienze Tecniche Mediche Applicatehypo-salivationPigmentationsPharmacologyOral cavitymucosal lesionDrug withdrawalPharmacokineticsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoveryHumansMedicinemedical liabilityDrug reactionpharmacokineticmedia_commonPharmacologyMouthDose-Response Relationship Drugbusiness.industrybisphosphonates.Mucosal lesionsMouth MucosadrugAdverse reactionmedicine.diseaseDermatologyPharmaceutical PreparationsTastePharmacodynamicsoral cavityadverse drug reaction oral cavityMouth DiseasesSalivationbusiness
researchProduct

Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteo…

2016

The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms. INTRODUCTION: The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada. METHODS: Baseline results are re…

Gastrointestinal DiseasesEndocrinology Diabetes and MetabolismHealth-related quality of lifeOsteoporosisFRACTURE RISKRISEDRONATE0302 clinical medicineEndocrinologyQuality of lifeBack pain030212 general & internal medicineProspective StudiesHEALTH PLANProspective cohort studyALENDRONATEOsteoporosis PostmenopausalPOPULATIONeducation.field_of_studyBone Density Conservation AgentsDiphosphonatesBISPHOSPHONATE THERAPYSettore MED/34 - Medicina Fisica E RiabilitativaTRACT SAFETYBisphosphonatesMiddle AgedEuropeDiabetes and MetabolismPOSTMENOPAUSAL WOMENPatient SatisfactionHealth ResourcesFemaleOriginal ArticlePostmenopausalmedicine.symptomBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of Life; Endocrinology Diabetes and Metabolismmedicine.medical_specialtyCanadaGastrointestinalPsychometricsPopulation030209 endocrinology & metabolismNOMedication Adherence03 medical and health sciencesInternal medicinemedicineHumanseducationBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of LifeAgedTreatment satisfactionbusiness.industryPERSISTENCEbisphosphonates gastrointestyinal osteoporosis postmenopausal treatment satisfactionBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfactionmedicine.diseaseRheumatologyCLINICAL-PRACTICEOrthopedic surgeryQuality of LifeOsteoporosisObservational studybusinessBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Endocrinology Diabetes and Metabolism
researchProduct

The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention

2018

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition that can considerably affect the quality of life of patients. Furthermore, even if its epidemiology and pathogenesis have still not been fully clarified, several risk factors related to MRONJ have been recognized in prevention protocols. Three main risk factors are as follows: (i) the type of ONJ-related medications: antiresorptive (e.g., Bisphosphonates, Denosumab) and antiangiogenic drugs (e.g., Bevacizumab, Sunitinib); (ii) the category of patient at MRONJ risk: cancer versus non-cancer patient; (iii) the typ…

Genetics and Molecular Biology (all)medicine.medical_specialtyBevacizumabImmunology and Microbiology (all)lcsh:MedicineAngiogenesis InhibitorsReview ArticleBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineQuality of lifeSettore MED/28 - Malattie OdontostomatologicheNeoplasmsOral and maxillofacial pathologyEpidemiologymedicineHumansIntensive care medicineAdverse effectBiochemistry Genetics and Molecular Biology (all)Bone Density Conservation AgentsDiphosphonatesGeneral Immunology and MicrobiologySunitinibbusiness.industrylcsh:R030206 dentistryGeneral Medicinemedicine.diseaseDenosumab030220 oncology & carcinogenesisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawBiochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)medicine.drug
researchProduct

Herbicidal derivatives of aminomethylenebisphosphonic acid. Part III. Structure-activity relationship.

1997

Derivatives of aminomethylenebisphosphonic acids constitute a class of promising herbicides. More than 40 N-substituted aminomethylenephosphonic acids were synthesized and evaluated for their herbicidal activity on common cress (Lepidium sativum L.) and cucumber (Cucumis sativus L.). Some of the tested compounds were found to exhibit strong herbicidal properties being equal in activity with the popular herbicide glyphosate as well as parent N-pyridylaminomethylenephosphonic acids. N-Substituted iminodi(methylenephosphonic) acids, which may be considered as close analog of glyphosate, were inactive toward test plants.

GlyphosatebiologyShikimate pathwayPlant physiologyBiological activityPlant ScienceBisphosphonatesbiology.organism_classificationChemical synthesisLepidium sativumchemistry.chemical_compoundBiochemistrychemistryShikimate pathway; Glyphosate; BisphosphonatesGlyphosateShikimate pathwayOrganic chemistryStructure–activity relationshipAgronomy and Crop ScienceCucumis
researchProduct

Knowledge of bisphosphonate-related osteonecrosis of the Jawsamong Mexican dentists

2017

Background Bisphosphonate-related osteonecrosis is an infrequent but potentially serious complication. Its treatment remains complex, and in some cases can be mutilating. Prevention, a correct diagnosis and opportune management are crucial. Material and Methods A cross-sectional study was made, interviewing 410 dentists with the aim of assessing their knowledge of the subject. Results Practically all of the dental professionals (99.7%) were found to lack sufficient knowledge of the prevention, diagnosis and management of bisphosphonate-related osteonecrosis. Conclusions Actions including increased diffusion in the professional media and inclusion of the subject in training programs are need…

Health Knowledge Attitudes Practicemedicine.medical_specialtyCross-sectional studymedicine.medical_treatmentMEDLINEDentistryHealth knowledge03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansIntensive care medicineSelf reportMexicoGeneral Dentistrybusiness.industryResearch030206 dentistryBisphosphonateMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Cross-Sectional StudiesOtorhinolaryngologyDentistry030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgerySelf ReportbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

IMAGING FINDINGS SYSTEMATIZATION AND IMAGING STAGING PROPOSAL IN BISPHOSPHONATES ASSOCIATED OSTEOMYLITIS/OSTEONECROSIS OF THE JAWS

2011

INTRODUZIONE I Bifosfonati (BPs), farmaci analoghi al pirofosfato, sono usati nel trattamento dell’osteoporosi, nella malattia di Paget, nel mieloma multiplo e nelle metastasi ossee. Sebbene siano molto utili nella sintomatologia osteolitica, dal 2003 è stata descritta la correlazione tra la loro somministrazione e l’insorgenza dell’osteonecrosi dei mascellari (BRONJ). Il nostro studio si propone di descrivere la superiorità delle immagini TC nei pazienti in cura con BPs affetti da BRONJ, e di raggruppare gli stessi in accordo con una classificazione radiologica basata sulla presenza o meno dei segni dell’osteomielite/osteonecrosi e delle successive complicanze. Si dimostra, inoltre, l’impo…

IMAGING FINDINGS SYSTEMATIZATION AND IMAGING STAGING PROPOSAL IN BISPHOSPHONATES ASSOCIATED OSTEOMYLITIS/OSTEONECROSIS OF THE JAWSSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Platelet-Rich Plasma (PRP) in Dental Extraction of Patients at Risk of Bisphosphonate-Related Osteonecrosis of the Jaws: A Two-Year Longitudinal Study

2020

: Dental extraction has often been described as the main trigger event of osteonecrosis of the jaws (ONJ). This longitudinal hospital-based study aimed to evaluate the outcome at 2 years of a standardized medical-surgical protocol for dental extraction, combined with platelet rich-plasma (PRP) application, compared with conventional protocol not combined with PRP or any other autologous platelet concentrate in cancer (ONC) and osteometabolic (OST) patients, at risk of bisphosphonate (BP)-related ONJ. Twenty patients were consecutively recruited: six received BPs for cancer skeletal-related events (34.17 &plusmn

Longitudinal studymedicine.medical_specialtybisphosphonatePRPmedicine.medical_treatmentONJosteonecrosis of the jawslcsh:TechnologyMetabolic bone diseaselcsh:Chemistry03 medical and health sciences0302 clinical medicineSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineGeneral Materials ScienceAutologous plateletProspective cohort studyInstrumentationbisphosphonateslcsh:QH301-705.5Fluid Flow and Transfer Processesbusiness.industrylcsh:TProcess Chemistry and TechnologyGeneral EngineeringCancerplatelet-rich plasma030206 dentistryBisphosphonatemedicine.diseaselcsh:QC1-999Computer Science Applicationsosteonecrosis of the jawDental extractionlcsh:Biology (General)lcsh:QD1-999lcsh:TA1-2040030220 oncology & carcinogenesisPlatelet-rich plasmadental extractionbusinesslcsh:Engineering (General). Civil engineering (General)lcsh:PhysicsApplied Sciences
researchProduct

Systematic study of the physicochemical properties of a homologous series of aminobisphosphonates

2012

ABSTRACT: Aminobisphosphonates, e.g., alendronate and neridronate, are a well known class of molecules used as drugs for various bone diseases. Although these molecules have been available for decades, a detailed understanding of their most important physicochemical properties under comparable conditions is lacking. In this study, ten aminobisphosphonates, H2N(CH2)nC(OH)[P(O)(OH)2]2, in which n = 2-5, 7-11 and 15 have been synthesized. Their aqueous solubility as a function of temperature and pH, pKa-values, thermal stability, IR absorptions, and NMR spectral data for both liquid (1H, 13C, 31P-NMR) and solid state (13C, 15N and 31P-CPMAS NMR) were determined. Peer reviewed

Magnetic Resonance Spectroscopy116 Chemical sciencesSolid-statePharmaceutical Sciencephysicochemical properties010402 general chemistry01 natural sciencesArticleAnalytical Chemistrylcsh:QD241-441Homologous serieschemistry.chemical_compoundlcsh:Organic chemistryComputational chemistrybisphosphonates; aqueous solubility; pKa; physicochemical propertiesaqueous solubilityDrug DiscoveryAqueous solubilityMoleculeOrganic chemistrypKaThermal stabilityPhysical and Theoretical ChemistrySolubilitySpectral datata116bisphosphonatesAlendronateDiphosphonates010405 organic chemistryChemistryOrganic ChemistryTemperaturebisphosphonates aqueous solubility pKa physicochemical propertiesWaterNuclear magnetic resonance spectroscopyHydrogen-Ion Concentration0104 chemical sciences3. Good healthSolubilityChemistry (miscellaneous)Molecular Medicine
researchProduct

Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study

2019

The patients’ persistence with osteoporosis treatments is low. This retrospective, multicenter survey showed that almost 30% of osteoporotic patients discontinued the treatment within the first 6 months and that those taking drinkable bisphosphonates were less likely to interrupt the therapy; instead, the use of generic bisphosphonates was associated to a more precocious interruption. Purpose: Low persistence with osteoporosis medications is associated with higher fracture risk. This study aimed to assess the persistence to treatment with oral bisphosphonates among Italian osteoporotic patients under treatment for at least 6 months and to evaluate whether the different oral formulations of …

MaleAgingmedicine.medical_specialtyGeneric drugmedicine.medical_treatmentOsteoporosisDrinkable bisphosphonates; Generic drug; Oral bisphosphonates; Osteoporosis; PersistenceAdministration OralPersistence (computer science)Medication AdherencePersistence03 medical and health sciencesFractures Bone0302 clinical medicineInternal medicineGeneric drugmedicineHumansDrinkable bisphosphonatesGeneric drugOral bisphosphonatesOsteoporosisPersistence030212 general & internal medicineMedical prescriptionAdverse effectAgedRetrospective StudiesOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryOral bisphosphonatesSettore MED/34 - Medicina Fisica E RiabilitativaBisphosphonateMiddle Agedmedicine.diseaseDiscontinuationLogistic ModelsItalyCase-Control StudiesOsteoporosisFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryOsteoporotic FracturesDrinkable bisphosphonates
researchProduct